Arabic Arabic English English French French German German
dark

Vanda Pharmaceuticals Settles HETLIOZ® Patent Litigation with MSN

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it has entered into a License Agreement (the License Agreement) with MSN Pharmaceuticals Inc., MSN Laboratories Private Limited (together MSN) and Impax Laboratories LLC (Impax) to resolve Vanda’s patent litigation against MSN regarding MSN’s Abbreviated New Drug Application seeking approval of its generic version of Vanda’s HETLIOZ® (tasimelteon). Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Global Rare Disease Drug Market Size Clinical Trials Insight 2028

Next Post

Bioengineered Nanoparticles Show Promise for Fibrinogen Manufacture, says Journal of Pharmaceutical Analysis Study

Related Posts
Total
0
Share